On Jan. 23, Johnson & Johnson
- Revenues of $53.3 billion, and earnings per share of $3.73, were very close to expectations. Taking into account one-time items from its acquisition of Pfizer's
(NYSE:PFE) consumer products division and the Guidant breakup fee, earnings per share were $3.76 for the year.
- Gross and operating margins declined slightly, but both are still very healthy, and nothing to complain about.
- Sales growth in the company's consumer products division was 7.5% overall, driven by 10.9% growth in international markets. That's very strong performance, especially considering that the acquisition of Pfizer's consumer-products business did not close until December.
- JNJ is the fifth-most rated stock in Motley Fool CAPS, with a solid four-star rating.
(Figures in millions, except per-share data)
Income Statement Highlights
Avg. Est. |
FY 2006 |
FY 2005 |
Change |
|
---|---|---|---|---|
Sales |
$53,330 |
$53,324 |
$50,514 |
5.6% |
Net Profit |
-- |
$11,053 |
$10,060 |
9.9% |
EPS |
$3.74 |
$3.73 |
$3.35 |
11.3% |
Diluted Shares |
-- |
2,961 |
3,003 |
(1.4%) |
Get back to basics with a look at the income statement.
Margin Checkup
FY 2006 |
FY 2005 |
Change* |
|
---|---|---|---|
Gross Margin |
71.76% |
72.38% |
(0.62) |
Operating Margin |
24.66% |
24.68% |
(0.02) |
Net Margin |
20.73% |
19.92% |
0.81 |
Margins are the earnings engine. See how they work.
Balance Sheet and Cash Flow Highlights
There's no Band-Aid for this boo-boo: The company declined to provide either a balance sheet or a cash flow statement.
Learn the ways of the balance sheet. Then, find out why Fools always follow the money.
Related Companies:
-
AstraZeneca
(NYSE:AZN) -
Novartis
(NYSE:NVS) -
Abbott Laboratories
(NYSE:ABT) -
Boston Scientific
(NYSE:BSX) -
Procter & Gamble
(NYSE:PG)
Related Foolishness:
- Foolish Fundamentals: Margins
- Foolish Fundamentals: Enterprise Value
- Foolish Fundamentals: Free Cash Flow
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
Johnson & Johnson is a Motley Fool Income Investor selection, while Pfizer is a Motley Fool Inside Value pick. Try any of our Foolish newsletters free for 30 days.
At the time of publication, Nathan Parmelee owned shares of Johnson & Johnson. Fool rules are here.